
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9362003/publications.pdf Version: 2024-02-01



FELICA COSMAN

#	Article	IF	CITATIONS
1	Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial. Osteoporosis International, 2022, 33, 239-250.	3.1	10
2	Denosumab in the Treatment of Osteoporosis: 10ÂYears Later: A Narrative Review. Advances in Therapy, 2022, 39, 58-74.	2.9	49
3	Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. Bone, 2022, 157, 116342.	2.9	6
4	Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporosis International, 2022, 33, 1243-1256.	3.1	38
5	Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. Osteoporosis International, 2022, 33, 1703-1714.	3.1	9
6	Romosozumab for the treatment of postmenopausal osteoporosis. , 2021, , 1827-1833.		0
7	Teriparatide and abaloparatide treatment for osteoporosis. , 2021, , 1757-1769.		0
8	Long-term treatment strategies and goal-directed therapy. , 2021, , 1867-1872.		2
9	Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?. Current Osteoporosis Reports, 2021, 19, 189-205.	3.6	18
10	Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. Osteoporosis International, 2021, 32, 1879-1888.	3.1	3
11	Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals. JBMR Plus, 2021, 5, e10546.	2.7	3
12	Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. Journal of Bone and Mineral Research, 2020, 35, 219-225.	2.8	15
13	Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radius. Bone, 2020, 132, 115211.	2.9	6
14	Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3384-3395.	3.6	24
15	Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?. Osteoporosis International, 2020, 31, 2321-2335.	3.1	16
16	Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend. Menopause, 2020, 27, 1137-1142.	2.0	5
17	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Current Medical Research and Opinion, 2020, 36, 1861-1872.	1.9	12
18	No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients. Bone Reports, 2020, 12, 100253.	0.4	5

FELICA COSMAN

#	Article	IF	CITATIONS
19	Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. Endocrine Practice, 2020, 26, 777-786.	2.1	34
20	Modelingâ€Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. Journal of Bone and Mineral Research, 2020, 35, 1282-1288.	2.8	30
21	Biomechanical Computed Tomography analysisÂ(BCT) for clinical assessment of osteoporosis. Osteoporosis International, 2020, 31, 1025-1048.	3.1	68
22	Loading modality and age influence teriparatide-induced bone formation in the human femoral neck. Bone, 2020, 136, 115373.	2.9	5
23	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. Journal of Bone and Mineral Research, 2020, 36, 1225-1234.	2.8	14
24	<i>T</i> â€Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. Journal of Bone and Mineral Research, 2020, 35, 1333-1342.	2.8	32
25	Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. Osteoporosis International, 2019, 30, 1187-1194.	3.1	25
26	Relationship Between Bone Mineral Density <i>T</i> -Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. Journal of Bone and Mineral Research, 2019, 34, 1033-1040.	2.8	79
27	The evolving role of anabolic therapy in the treatment of osteoporosis. Current Opinion in Rheumatology, 2019, 31, 376-380.	4.3	12
28	Administration of teriparatide for four years cyclically compared to two years daily in treatment NaÃ⁻ve and alendronate treated women. Bone, 2019, 120, 246-253.	2.9	15
29	Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. Journal of Bone and Mineral Research, 2019, 34, 810-816.	2.8	22
30	Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause, 2018, 25, 767-771.	2.0	31
31	FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. Journal of Bone and Mineral Research, 2018, 33, 1219-1226.	2.8	108
32	Long-term treatment strategies for postmenopausal osteoporosis. Current Opinion in Rheumatology, 2018, 30, 420-426.	4.3	19
33	Parathyroid hormone and abaloparatide treatment for osteoporosis. Current Opinion in Endocrine and Metabolic Research, 2018, 3, 61-67.	1.4	3
34	ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2949-2957.	3.6	131
35	Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. Journal of Bone and Mineral Research, 2018, 33, 1407-1416.	2.8	56
36	OP0344â€Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab. , 2018, , .		0

#	Article	IF	CITATIONS
37	Results of a fracture liaison service on hip fracture patients in an open healthcare system. Aging Clinical and Experimental Research, 2017, 29, 331-334.	2.9	22
38	Unmasking romosozumab: response to commentsby Uzoigwe et al Osteoporosis International, 2017, 28, 2021-2022.	3.1	1
39	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis. Mayo Clinic Proceedings, 2017, 92, 200-210.	3.0	109
40	Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014. Osteoporosis International, 2017, 28, 1857-1866.	3.1	86
41	Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. Journal of Bone and Mineral Research, 2017, 32, 198-202.	2.8	181
42	Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40Âyears: results from the National Health and Nutrition Examination Survey (NHANES) 2013–2014supplementary presentation. Osteoporosis International, 2017, 28, 2319-2320.	3.1	10
43	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. Journal of Bone and Mineral Research, 2017, 32, 3-10.	2.8	127
44	Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. Journal of Bone and Mineral Research, 2017, 32, 17-23.	2.8	75
45	Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. Journal of Bone and Mineral Research, 2016, 31, 1518-1526.	2.8	35
46	Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis. JAMA - Journal of the American Medical Association, 2016, 316, 722.	7.4	618
47	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2016, 375, 1532-1543.	27.0	1,099
48	Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. Bone, 2016, 84, 113-119.	2.9	15
49	A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporosis International, 2016, 27, 377-386.	3.1	20
50	Effect of Teriparatide on Bone Formation in the Human Femoral Neck. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1498-1505.	3.6	33
51	The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 2015, 30, 934-944.	2.8	205
52	Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2769-2776.	3.6	33
53	Abaloparatide: a new anabolic therapy on the horizon. BoneKEy Reports, 2015, 4, 661.	2.7	13
54	Combination therapy for osteoporosis: a reappraisal. BoneKEy Reports, 2014, 3, 518.	2.7	45

#	Article	IF	CITATIONS
55	Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4546-4554.	3.6	109
56	Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2014, 29, 1-23.	2.8	1,424
57	Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 2014, 25, 2359-2381.	3.1	2,549
58	Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches. Current Osteoporosis Reports, 2014, 12, 385-395.	3.6	79
59	Goal-directed treatment of osteoporosis. Journal of Bone and Mineral Research, 2013, 28, 433-438.	2.8	54
60	Determinants of stress fracture risk in United States Military Academy cadets. Bone, 2013, 55, 359-366.	2.9	129
61	Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. Journal of Bone and Mineral Research, 2013, 28, 1328-1336.	2.8	76
62	Changes in vitamin D metabolites during teriparatide treatment. Bone, 2012, 50, 1368-1371.	2.9	15
63	The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 2012, 27, 243-254.	2.8	552
64	Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research, 2012, 27, 702-712.	2.8	26
65	Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. Journal of Bone and Mineral Research, 2012, 27, 963-974.	2.8	94
66	Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 2011, 26, 503-511.	2.8	291
67	Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporosis International, 2010, 21, 399-408.	3.1	239
68	Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. Journal of Bone and Mineral Research, 2010, 25, 2267-2294.	2.8	994
69	Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 151-158.	3.6	168
70	Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates. Endocrine Practice, 2009, 15, 483-493.	2.1	23
71	Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3772-3780.	3.6	153
72	Retreatment With Teriparatide One Year After the First Teriparatide Course in Patients on Continued Long-Term Alendronate. Journal of Bone and Mineral Research, 2009, 24, 1110-1115.	2.8	44

#	Article	IF	CITATIONS
73	Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporosis International, 2008, 19, 529-535.	3.1	45
74	Measuring serum calcium before and after teriparatide treatment: authors' response. Osteoporosis International, 2008, 19, 1809-1809.	3.1	0
75	Relationship between growth hormone in vivo bioactivity, the insulin-like growth factor-I system and bone mineral density in young, physically fit men and women. Growth Hormone and IGF Research, 2008, 18, 439-445.	1.1	15
76	Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: The role of comparative studies and implications for future studies. Clinical Therapeutics, 2007, 29, 1116-1127.	2.5	10
77	Vitamin D Economy in Blacks. Journal of Bone and Mineral Research, 2007, 22, V34-V38.	2.8	48
78	Effects Of a One-Month Treatment With PTH(1-34) on Bone Formation on Cancellous, Endocortical, and Periosteal Surfaces of the Human Ilium. Journal of Bone and Mineral Research, 2007, 22, 495-502.	2.8	219
79	Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine, 2007, 356, 1809-1822.	27.0	2,536
80	Relationship Between Bioassayable Growth Hormone, The Insulin‣ike Growth Factorâ€I System and Bone Mineral Density in Men and Women. FASEB Journal, 2007, 21, A1421.	0.5	0
81	Anabolic therapy for osteoporosis: Parathyroid hormone. Current Rheumatology Reports, 2006, 8, 63-69.	4.7	13
82	A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide. Journal of Bone and Mineral Research, 2005, 21, 366-373.	2.8	248
83	Anabolic therapy for osteoporosis: Parathyroid hormone. Current Osteoporosis Reports, 2005, 3, 143-149.	3.6	16
84	Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. New England Journal of Medicine, 2005, 353, 566-575.	27.0	245
85	Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thrombosis Research, 2005, 116, 1-13.	1.7	84
86	Anabolic therapy for osteoporosis: Parathyroid hormone. Current Osteoporosis Reports, 2005, 3, 143-149.	3.6	0
87	Therapeutic potential of parathyroid hormone. Current Osteoporosis Reports, 2004, 2, 5-11.	3.6	26
88	Selective estrogen-receptor modulators. Clinics in Geriatric Medicine, 2003, 19, 371-379.	2.6	32
89	Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1150-1156.	3.6	228
90	Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study. Journal of Bone and Mineral Research, 2001, 16, 1846-1853.	2.8	580

#	Article	IF	CITATIONS
91	Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal. Journal of Bone and Mineral Research, 2001, 16, 925-931.	2.8	294
92	Biochemical Responses of Bone Metabolism to 1,25-Dihydroxyvitamin D Administration in Black and White Women. Osteoporosis International, 2000, 11, 271-277.	3.1	35
93	Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3069-3076.	3.6	331
94	Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3076-3081.	3.6	150
95	Parathyroid Hormone Secretory Response to EDTA-Induced Hypocalcemia in Black and White Premenopausal Women. Calcified Tissue International, 1999, 65, 257-261.	3.1	13
96	Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women. Journal of Bone and Mineral Research, 1998, 13, 1051-1055.	2.8	108
97	Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence. Calcified Tissue International, 1998, 62, 475-480.	3.1	91
98	Parathyroid Responsivity in Postmenopausal Women with Osteoporosis During Treatment with Parathyroid Hormone1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 788-790.	3.6	14
99	Bone Mass and Vitamin D Deficiency in Adults with Advanced Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1892-1899.	5.6	167
100	Fracture history and bone loss in patients with MS. Neurology, 1998, 51, 1161-1165.	1.1	171
101	Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet, The, 1997, 350, 550-555.	13.7	713
102	Histomorphometric Assessment of Bone Mass, Structure, and Remodeling: A Comparison Between Healthy Black and White Premenopausal Women. Journal of Bone and Mineral Research, 1997, 12, 948-957.	2.8	78
103	Resistance to Bone Resorbing Effects of PTH in Black Women. Journal of Bone and Mineral Research, 1997, 12, 958-966.	2.8	173
104	Bone density change and biochemical indices of skeletal turnover. Calcified Tissue International, 1996, 58, 236-243.	3.1	95
105	Bone Density Change and Biochemical Indices of Skeletal Turnover. Calcified Tissue International, 1996, 58, 236-243.	3.1	9
106	Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: Effects of estrogen therapy. Journal of Bone and Mineral Research, 1995, 10, 594-600.	2.8	8
107	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. Journal of Bone and Mineral Research, 1995, 10, 1393-1399.	2.8	127
108	Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women Journal of Clinical Endocrinology and Metabolism, 1994, 78, 939-943.	3.6	39

#	Article	IF	CITATIONS
109	High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. Journal of Bone and Mineral Research, 1994, 9, 1097-1105.	2.8	129
110	Relationships between quantitative histological measurements and noninvasive assessments of bone mass. Bone, 1992, 13, 237-242.	2.9	42
111	Comparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry. Calcified Tissue International, 1992, 51, 352-355.	3.1	25
112	Bone mass and body composition in normal women. Journal of Bone and Mineral Research, 1992, 7, 55-63.	2.8	199
113	Radiographic absorptiometry: A simple method for determination of bone mass. Osteoporosis International, 1991, 2, 34-38.	3.1	117
114	Parathyroid Hormone-(1-34) [PTH-(l-34)]: Demonstration of Suppression of Endogenous Secretion Using Immunoradiometric Intact PTH-(l-84) Assay*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 1345-1351.	3.6	52
115	Hypercalcaemia causing declining cognitive function in a head injured patient. Brain Injury, 1989, 3, 315-318.	1.2	2